HSF1 Degrader Program

About Sisu Pharma

Sisu Pharma is a private, preclinical-stage biotech founded in 2018 and based in San Diego, California. The company is pioneering a novel therapeutic strategy by directly targeting the transcription factor HSF1, a historically 'undruggable' master regulator of cellular stress protection. Its proprietary HI-LiTe platform enables the discovery of compounds that can either degrade or activate HSF1, with applications in oncology, neurodegeneration, and infection. Led by a team of seasoned scientists and drug developers, Sisu is advancing first-in-class compounds that have shown exceptional efficacy in resistant cancer models.

Therapeutic Areas